IntroDia^™ is the largest multinational survey of its kind to date which aims to investigate early conversations between physicians and people living with type 2 diabetes and how these conversations may correlate with the individuals’ wellbeing and self-care. Launched in 2013, the survey includes insights from more than 10,000 individuals with type 2 diabetes and more than 6,700 treating physicians across 26 countries. Learn more about the results.

The study is investigating conversations at two distinct milestones: the point of diagnosis of type 2 diabetes, and the moment when additional therapy may be required. The survey insights will be used to develop tools to provide additional support for physicians and people with type 2 diabetes for their early conversations. IntroDia^™ was developed by Boehringer Ingelheim and Eli Lilly and Company together with an international multidisciplinary Advisory Board, and in partnership with the International Diabetes Federation (IDF).